TY - JOUR AU - Bower, M. AU - Dalla Pria, A. AU - Coyle, C. AU - Andrews, E. AU - Tittle, V. AU - Dhoot, S. PY - 2014 DA - 2014// TI - Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.51.6757 DO - 10.1200/JCO.2013.51.6757 ID - Bower2014 ER - TY - STD TI - Katano H, Imamura A, Kato H, Ozawa K, Nagata N, Teruya K, et al. Diagnosis and guidance on HHV-8 related diseases such as AIDS related Kaposi sarcoma. http://www.acc.go.jp/doctor/010/020/HHV8_tebiki201403.pdf [accessed 17 May 2019]. UR - http://www.acc.go.jp/doctor/010/020/HHV8_tebiki201403.pdf ID - ref2 ER - TY - JOUR AU - Cianfrocca, M. AU - Lee, S. AU - Roenn, J. AU - Tulpule, A. AU - Dezube, B. J. AU - Aboulafia, D. M. PY - 2010 DA - 2010// TI - Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy JO - Cancer. VL - 116 UR - https://doi.org/10.1002/cncr.25362 DO - 10.1002/cncr.25362 ID - Cianfrocca2010 ER - TY - JOUR AU - Martin-Carbonero, L. AU - Barrios, A. AU - Saballs, P. AU - Sirera, G. AU - Santos, J. AU - Palacios, R. PY - 2004 DA - 2004// TI - Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma JO - AIDS. VL - 18 UR - https://doi.org/10.1097/01.aids.0000131385.60974.b9 DO - 10.1097/01.aids.0000131385.60974.b9 ID - Martin-Carbonero2004 ER - TY - JOUR AU - Tulpule, A. AU - Groopman, J. AU - Saville, M. W. AU - Harrington, W. AU - Friedman-Kien, A. AU - Espina, B. M. PY - 2002 DA - 2002// TI - Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma JO - Cancer VL - 95 UR - https://doi.org/10.1002/cncr.10634 DO - 10.1002/cncr.10634 ID - Tulpule2002 ER - TY - STD TI - Prescribing Information for DOXORUBICIN HYDROCHLORIDE. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050467s073lbl.pdf [accessed 17 May 2019]. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050467s073lbl.pdf ID - ref6 ER - TY - JOUR AU - O'Brien, M. E. AU - Wigler, N. AU - Inbar, M. AU - Rosso, R. AU - Grischke, E. AU - Santoro, A. PY - 2004 DA - 2004// TI - CAELYX breast Cancer study group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer JO - Ann Oncol VL - 15 UR - https://doi.org/10.1093/annonc/mdh097 DO - 10.1093/annonc/mdh097 ID - O'Brien2004 ER - TY - STD TI - Prescribing Information for DOXIL. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050718s051lbl.pdf [accessed 17 May 2019]. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050718s051lbl.pdf ID - ref8 ER - TY - JOUR AU - Suzuki, J. AU - Sasahara, T. AU - Toshima, M. AU - Norizuki, M. AU - Onishi, T. AU - Okabe, T. PY - 2015 DA - 2015// TI - Usefulness of 18F-Fluorodeoxyglucose-position emission tomography with computed tomography and gallium-67 scintigraphy for detection of Kaposi sarcoma lesions in a 40-year-old Japanese man with AIDS JO - IDCases. VL - 2 UR - https://doi.org/10.1016/j.idcr.2015.05.001 DO - 10.1016/j.idcr.2015.05.001 ID - Suzuki2015 ER - TY - JOUR AU - Krown, S. E. AU - Metroka, C. AU - Wernz, J. C. PY - 1989 DA - 1989// TI - Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group oncology committee JO - J Clin Oncol VL - 7 UR - https://doi.org/10.1200/JCO.1989.7.9.1201 DO - 10.1200/JCO.1989.7.9.1201 ID - Krown1989 ER - TY - JOUR AU - Rahman, A. M. AU - Yusuf, S. W. AU - Ewer, M. S. PY - 2007 DA - 2007// TI - Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation JO - Int J Nanomedicine VL - 2 ID - Rahman2007 ER - TY - JOUR AU - Billingham, M. E. AU - Mason, J. W. AU - Bristow, M. R. AU - Daniels, J. R. PY - 1978 DA - 1978// TI - Anthracycline cardiomyopathy monitored by morphologic changes JO - Cancer Treat Rep VL - 62 ID - Billingham1978 ER - TY - JOUR AU - Bristow, M. R. AU - Mason, J. W. AU - Billingham, M. E. AU - Daniels, J. R. PY - 1978 DA - 1978// TI - Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization JO - Ann Intern Med VL - 88 UR - https://doi.org/10.7326/0003-4819-88-2-168 DO - 10.7326/0003-4819-88-2-168 ID - Bristow1978 ER - TY - JOUR AU - Tardi, P. G. AU - Boman, N. L. AU - Cullis, P. R. PY - 1996 DA - 1996// TI - Liposomal doxorubicin JO - J Drug Target VL - 4 UR - https://doi.org/10.3109/10611869609015970 DO - 10.3109/10611869609015970 ID - Tardi1996 ER - TY - JOUR AU - Harris, L. AU - Batist, G. AU - Belt, R. AU - Rovira, D. AU - Navari, R. AU - Azarnia, N. PY - 2002 DA - 2002// TI - TLC D-99 study group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma JO - Cancer. VL - 94 UR - https://doi.org/10.1002/cncr.10201 DO - 10.1002/cncr.10201 ID - Harris2002 ER - TY - JOUR AU - Klibanov, A. L. AU - Maruyama, K. AU - Torchilin, V. P. AU - Huang, L. PY - 1990 DA - 1990// TI - Amphipathic polyethylenglycols effectively prolong the circulation time of liposomes JO - FEBS Lett VL - 268 UR - https://doi.org/10.1016/0014-5793(90)81016-H DO - 10.1016/0014-5793(90)81016-H ID - Klibanov1990 ER - TY - JOUR AU - Gordon, A. N. AU - Fleagle, J. T. AU - Guthrie, D. AU - Parkin, D. E. AU - Gore, M. E. AU - Lacave, A. J. PY - 2001 DA - 2001// TI - Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.14.3312 DO - 10.1200/JCO.2001.19.14.3312 ID - Gordon2001 ER - TY - JOUR AU - Uyar, D. AU - Kulp, B. AU - Peterson, G. AU - Zanotti, K. AU - Markman, M. AU - Belinson, J. PY - 2004 DA - 2004// TI - Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies JO - Gynecol Oncol VL - 94 UR - https://doi.org/10.1016/j.ygyno.2004.03.024 DO - 10.1016/j.ygyno.2004.03.024 ID - Uyar2004 ER - TY - JOUR AU - Collins, Y. AU - Lele, S. PY - 2005 DA - 2005// TI - Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma JO - J Natl Med Assoc VL - 97 ID - Collins2005 ER - TY - JOUR AU - Kesterson, J. P. AU - Odunsi, K. AU - Lele, S. PY - 2010 DA - 2010// TI - High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies JO - Chemotherapy. VL - 56 UR - https://doi.org/10.1159/000312644 DO - 10.1159/000312644 ID - Kesterson2010 ER - TY - JOUR AU - Rabinovich, A. AU - Ramanakumar, A. V. AU - Lau, S. AU - Gotlieb, W. H. PY - 2015 DA - 2015// TI - Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasiability study JO - Acta Obstet Gynecol Scand VL - 94 UR - https://doi.org/10.1111/aogs.12642 DO - 10.1111/aogs.12642 ID - Rabinovich2015 ER - TY - JOUR AU - Hengge, U. R. AU - Esser, S. AU - Rudel, H. P. AU - Goos, M. PY - 2001 DA - 2001// TI - Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin JO - Eur J Cancer VL - 37 UR - https://doi.org/10.1016/S0959-8049(01)00053-3 DO - 10.1016/S0959-8049(01)00053-3 ID - Hengge2001 ER - TY - JOUR AU - Pein, F. AU - Sakiroglu, O. AU - Dahan, M. AU - Lebidois, J. AU - Merlet, P. AU - Shamsaldin, A. PY - 2004 DA - 2004// TI - Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy JO - Br J Cancer VL - 91 UR - https://doi.org/10.1038/sj.bjc.6601904 DO - 10.1038/sj.bjc.6601904 ID - Pein2004 ER - TY - JOUR AU - Skubitz, K. M. AU - Blaes, A. H. AU - Konety, S. H. AU - Francis, G. S. PY - 2017 DA - 2017// TI - Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value JO - Cancer Chemother Pharmacol VL - 80 UR - https://doi.org/10.1007/s00280-017-3420-8 DO - 10.1007/s00280-017-3420-8 ID - Skubitz2017 ER - TY - JOUR AU - Berry, G. AU - Billingham, M. AU - Alderman, E. AU - Richardson, P. AU - Torti, F. AU - Lum, B. PY - 1998 DA - 1998// TI - The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicin JO - Ann Oncol VL - 9 UR - https://doi.org/10.1023/A:1008216430806 DO - 10.1023/A:1008216430806 ID - Berry1998 ER - TY - JOUR AU - Gabizon, A. A. AU - Lyass, O. AU - Berry, G. J. AU - Wildgust, M. PY - 2004 DA - 2004// TI - Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies JO - Cancer Investig VL - 22 UR - https://doi.org/10.1081/CNV-200032899 DO - 10.1081/CNV-200032899 ID - Gabizon2004 ER - TY - JOUR AU - Safra, T. AU - Muggia, F. AU - Jeffers, S. AU - Tsao-Wei, D. D. AU - Groshen, S. AU - Lyass, O. PY - 2000 DA - 2000// TI - Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2 JO - Ann Oncol VL - 11 UR - https://doi.org/10.1023/A:1008365716693 DO - 10.1023/A:1008365716693 ID - Safra2000 ER - TY - JOUR AU - Polizzotto, M. N. AU - Uldrick, T. S. AU - Hu, D. AU - Yarchoan, R. PY - 2012 DA - 2012// TI - Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome JO - Front Microbiol VL - 3 UR - https://doi.org/10.3389/fmicb.2012.00073 DO - 10.3389/fmicb.2012.00073 ID - Polizzotto2012 ER -